Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention

Diabetes Care

Volumn 35, Issue 11, 2012, Pages 2194-2197

  Jeong, Young Hoon ^a,b   Tantry, Udaya S ^b   Park, Yongwhi ^a   Kwon, Tae Jung ^a   Park, Jeong Rang ^a   Hwang, Seok Jae ^a   Bliden, Kevin P ^a   Koh, Eun Ha ^a   Kwak, Choong Hwan ^a   Hwang, Jin Yong ^a   Kim, Sunjoo ^a   Gurbel, Paul A ^b  

^a Gyeongsang National University   (South Korea)

^b SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1;

ACUTE HEART INFARCTION; ALLELE; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING DISORDER; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; GENOTYPE; HEADACHE; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; ISCHEMIA; LOADING DRUG DOSE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT DURATION;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; TETRAZOLES; TICLOPIDINE;

EID: 84868089901     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-2351     Document Type: Article

References (15)

1. Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 2011;123:798-813
2. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010;376:1312-1319
3. Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006;174:1715-1722
4. Jeong YH, Tantry US, Bliden KP, Gurbel PA. Cilostazol to overcome high on-treatment platelet reactivity in korean patients treated with clopidogrel and calcium-channel blocker. Circ J 2011;75:2534-2536
5. Angiolillo DJ, Capranzano P, Ferreiro JL, et al. Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thromb Haemost 2011;106:253-262
6. Yoo HD, Cho HY, Lee YB. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1. Br J Clin Pharmacol 2010;69:27-37
7. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35(Suppl. 1):S64-S71
8. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009;53:1101-1109
9. Bonello L, Tantry US, Marcucci R, et al.; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-933
10. Ferreiro JL, Ueno M, Desai B, Capranzano P, Capodanno D, Angiolillo DJ. Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus. Rev Esp Cardiol 2012;65:105-106
11. Price MJ. Murray SS, Angiolillo DJ, et al. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol 2012;59:1928-1937
12. Mega JL, Hochholzer W, Frelinger AL 3rd, Kluk MJ, Angiolillo DJ, Kereiakes DJ. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011;306:2221-2228
13. Takagi H, Umemoto T. Benefit, rather than safety, of cilostazol for long-term mortality in patients undergoing percutaneous coronary intervention: a metaanalysis of randomized trials. Int J Cardiol 2011;153:74-76
14. El Ghannudi S, Ohlmann P, Jesel L, et al. Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention. Atherosclerosis 2011;217:465-472
15. Hess K, Grant PJ. Inflammation and thrombosis in diabetes. Thromb Haemost 2011;105(Suppl. 1):S43-S54